Sapience Therapeutics will participate in SVB Leerink Biopharma Private Company Connect


HARRISON, NY, March 15, 2022 /PRNewswire/ — Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of small protein therapeutics to treat difficult-to-treat cancers, today announced that management will participate in one-on-one meetings with investors at the SVB Leerink Biopharma Private Company Connect event, being held virtually March 29-312022.

About Sapience Therapeutics
Sapience Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on the discovery and development of small protein therapeutics for key unmet medical needs, particularly high-mortality cancers. Sapience’s approach has the potential to target intracellular interactions that are traditionally considered ‘untreatable targets’. Its lead program, ST101, is a small protein C/EBPβ antagonist that has demonstrated phase 1 clinical proof of concept with a confirmed partial response (PR). ST101 is currently being evaluated in Phase 2 of an ongoing Phase 1-2 clinical study with potential applications in various solid tumors and hematological malignancies. For more information about Sapience Therapeutics, please visit and engage with us on LinkedIn.

Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements contained herein other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties (including with respect to Sapience’s preclinical and clinical development programs). These forward-looking statements are based on management’s current expectations, and actual results and future events may differ materially due to certain factors, including, without limitation, our ability to obtain additional funds, meet applicable regulatory standards and to receive required regulatory approvals. . Forward-looking statements speak only as of the date of this press release. Sapience disclaims any obligation to update forward-looking statements as a result of new information, future events, changes in assumptions or otherwise, except as required by law.

Sapience Therapeutics, Inc.
Barry KapellPhD, MBA
President and CEO
[email protected]

Media and investor contact:
Amy Conrad
tip of the juniper
(858) 366-3243
[email protected]

SOURCESapience Therapeutics, Inc.

Source link


Comments are closed.